Specific sequence mutations in a long-lasting rhIFN-α2b version reduce in vitro and in vivo immunogenicity and increase in vitro protein stability
For decades, recombinant human interferon alpha (rhIFN-α2b) has been used to treat emerging and chronic viral diseases. However, rhIFN-α2b is immunogenic and has a short in vivo half-life. To solve these limitations, two long-lasting hyperglycosylated proteins with reduced immunogenicity were develo...
Main Authors: | Eduardo Federico Mufarrege, Lucía Carolina Peña, Marina Etcheverrigaray, Anne S. De Groot, William Martin |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2023-03-01
|
Series: | Heliyon |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2405844023018777 |
Similar Items
-
In silico methods for immunogenicity risk assessment and human homology screening for therapeutic antibodies
by: Aimee E. Mattei, et al.
Published: (2024-12-01) -
Identification of immunodominant T cell epitopes induced by natural Zika virus infection
by: Christopher S. Eickhoff, et al.
Published: (2023-08-01) -
Significance of the interferon (IFN) in the therapy
by: Sabina Mahmutović, et al.
Published: (2004-11-01) -
Overexpression of the recombinant human interferon-beta (rhIFN-β) gene in tobacco chloroplasts
by: Asghar Feizi, et al.
Published: (2021-12-01) -
Potency, immunogenicity, and efficacy of rabies vaccine: In vitro and in vivo approach
by: Fahima Akter, et al.
Published: (2024-02-01)